X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CADILA HEALTHCARE ASTRAZENECA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 136.9 23.7 577.0% View Chart
P/BV x 20.8 6.0 348.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CADILA HEALTHCARE
Mar-17
ASTRAZENECA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,285460 279.3%   
Low Rs634305 207.9%   
Sales per share (Unadj.) Rs189.692.1 205.8%  
Earnings per share (Unadj.) Rs-0.214.8 -1.4%  
Cash flow per share (Unadj.) Rs3.818.5 20.8%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.668.0 101.0%  
Shares outstanding (eoy) m25.001,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.2 121.9%   
Avg P/E ratio x-4,712.725.8 -18,254.7%  
P/CF ratio (eoy) x249.620.7 1,205.8%  
Price / Book Value ratio x14.05.6 248.5%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m23,988391,581 6.1%   
No. of employees `0001.616.9 9.2%   
Total wages/salary Rs m1,60515,002 10.7%   
Avg. sales/employee Rs Th3,040.25,594.5 54.3%   
Avg. wages/employee Rs Th1,029.2890.1 115.6%   
Avg. net profit/employee Rs Th-3.3899.9 -0.4%   
INCOME DATA
Net Sales Rs m4,74094,295 5.0%  
Other income Rs m921,286 7.2%   
Total revenues Rs m4,83295,581 5.1%   
Gross profit Rs m-13019,036 -0.7%  
Depreciation Rs m1013,750 2.7%   
Interest Rs m0450 0.0%   
Profit before tax Rs m-13916,122 -0.9%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139-3 -4,630.0%   
Tax Rs m51,289 0.4%   
Profit after tax Rs m-515,168 -0.0%  
Gross profit margin %-2.720.2 -13.6%  
Effective tax rate %-3.78.0 -45.8%   
Net profit margin %-0.116.1 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,72660,223 4.5%   
Current liabilities Rs m2,43553,058 4.6%   
Net working cap to sales %6.17.6 80.9%  
Current ratio x1.11.1 98.6%  
Inventory Days Days7470 105.6%  
Debtors Days Days4188 46.2%  
Net fixed assets Rs m1,03572,984 1.4%   
Share capital Rs m501,024 4.9%   
"Free" reserves Rs m94268,576 1.4%   
Net worth Rs m1,71669,600 2.5%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m4,156152,207 2.7%  
Interest coverage xNM36.8-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.6 184.1%   
Return on assets %-0.110.3 -1.2%  
Return on equity %-0.321.8 -1.4%  
Return on capital %017.9 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37521,280 1.8%   
Fx outflow Rs m47010,874 4.3%   
Net fx Rs m-9610,406 -0.9%   
CASH FLOW
From Operations Rs m-813,495 -0.1%  
From Investments Rs m-146-29,103 0.5%  
From Financial Activity Rs m86223,158 3.7%  
Net Cashflow Rs m7097,556 9.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 15.7 5.9 266.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   12,856 44,069 29.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 20, 2018 10:45 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS